Keywords
platelet-rich plasma
PASI score
DLQI score
How to Cite
Abstract
Psoriasis vulgaris is an autoimmune disease that is influenced by multifactor, namely environmental, genetic (HLA-Cw6), and immune system dysregulation (IL-17 or IL-22), resulting in increased proliferation of keratinosit in the epidermis. Histologically characterized by parakeratosis, hyperkeratosis, elongated rete ridge, Monro micro abscess, and Kogoj micro abscess. The clinical picture is red patches with thick scales, especially in the trauma area. Platelet Rich Plasma (PRP) is an autologous preparation of platelets that strengthens in plasma and is a powerful anti-inflammatory agent. The immunomodulatory and anti-inflammatory effects of PRP are believed to play a role in the treatment of chronic inflammation patients. One of the important mediators in the pathogenesis of psoriasis is nuclear factor kappa B (NF-κB) and PRP exerting an inhibitory effect on NF-κB. The aim of the study was to assess the effect of PRP on the severity and quality of life of psoriasis vulgaris patients. The design of this study is a paired numerical comparative analysis using two groups with two measurements. The research design was a randomized, undisguised clinical trial and a parallel design. The study lasted for 6 weeks. Sampling was done by total sampling involving 20 psoriasis Vulgaris patients, then divided into two groups: intervention group and control group. The test group received 2 PRP injections and topical combination therapy (salicylic acid 3% + Vaseline album cream), while the control group only received topical combination therapy. The results of this study found a decrease in PASI and DLQI scores in the intervention group compared to the control group (p<0.005). This study concludes that the administration of PRP can reduce the severity of psoriasis Vulgaris as well as improve the quality of life of psoriasis Vulgaris patients.
References
Armstrong, A.W., Mehta, M.D., Schupp, C.W., Gondo, G.C., Bell, S.J., & Griffiths, C.E.M. (2021). Psoriasis Prevalence in Adults in the United States. JAMA Dermatol, 157(8), 940-946. https://doi.org/10.1001/jamadermatol.2021.2007.
Armstrong, A. W., Harskamp, C. T., & Armstrong, E. J. (2012). The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutrition & Diabetes, 2(12), 54. https://doi.org/10.1038/nutd.2012.26.
Armstrong, E. J., Harskamp, C. T., & Armstrong, A. W. (2013). Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies, J Am Heart Assoc, 2(2). https://doi.org/10.1161/jaha.113.000062.
Arshdeep & Sendhil Kumaran, M. (2014). Platelet-rich plasma in dermatology: Boon or a bane?. Indian J Dermatol Venereol Leprol, 80(1), 5–14. https://doi.org/10.4103/0378-6323.125467.
Budianti, W. K., Anindya, S., Debinta, A., Novianto, E., Fitri, E., & Halim, E. (2019). Kesesuaian Tata Laksana Psoriasis dengan Panduan Praktik Klinis (PPK) di RSUPN Dr. Cipto Mangunkusumo. Media Dermanto Venereologiva Indonesiana, 46, 172–177. http://dx.doi.org/10.33820/mdvi.v46i4.77.
Chakravdhanula, U., Anbarasu, K., Verma, V.K., & Beevi, S.S. (2016). Clinical efficacy of platelet rich plasma in combination with methotrexate in chronic plaque psoriatic patients. Dermatol Ther, 29(6), 446-450. https://doi.org/10.1111/dth.12388.
Coates, L. C. & Helliwell, P. S. (2017). Psoriatic arthritis: state of the art review. Clinical Medicine, 17(1), 65–70. https://doi.org/10.7861/clinmedicine.17-1-65.
El-Sharkawy, H., Kantarci, A., Deady, J., Hasturk, H., Liu, H., Alshahat, M., & Van Dyke, T.E. (2007). Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol, 78(4), 661–9. https://doi.org/10.1902/jop.2007.060302.
Gudjonsson, J. E. & Elder, J. T. (2017). Psoriasis, in Fitzpatrick’s Dermatology In General Medicine. 7th edn. Philadelphia: McGraw Hill Education Medical, 169–193.
Gudjonsson, J. E. & Elder, J. T. (2019). Psoriasis, in Fitzpatrick’s Dermatology. 9th edn. Philadelphia: Mc Graw Hill Medical, 457.
Kauhl, W., Pototschnig, H. & Paasch, U. (2021). Can Platelet-Rich Plasma Reduce the Burden of Inflammatory Skin Diseases Such as Psoriasis and Atopic Dermatitis?. Cureus, 13(10), 6–13. https://doi.org/10.7759%2Fcureus.18472.
Liang, S. E., Cohen, J. M., & Ho, R. S. (2019). Psoriasis and suicidality: A review of the literature. Dermatologic Therapy, 32(1), 12771. https://doi.org/10.1111/dth.12771.
Nijsten, T., Margolis, D.J., Feldman, S.R., Rolstad, T., & Stern, R.S. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol, 52(3), 434–44. https://doi.org/10.1016/j.jaad.2004.10.862.
Parisi, R., Iskandar, I.Y.K, Kontopantelis, E., Augustin, M., Griffiths, C.E.M., & Ashcroft, D.M. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. The BMJ, 369. https://doi.org/10.1136/bmj.m1590.
Peng, G. L. (2019). Platelet-Rich Plasma for Skin Rejuvenation: Facts, Fiction, and Pearls for Practice’, Facial Plastic Surgery Clinics of North America, 27(3), 405–411. https://doi.org/10.1016/j.fsc.2019.04.006.
Siswati, A. S. (2021). Psoriasis, in Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI), 294.
Widaty, S. (2017) ‘Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia’. Jakarta: Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI).
World Health Organization. (2017). Global report on psoriasis, World Health Organization.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Nanda Earlia